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Purpose: The purposes of this study were development and validation of an expert system (ES) 
aimed at supporting the diagnosis of chronic obstructive lung disease (COLD).
Methods: A questionnaire and a WebFlex code were developed and validated in silico. An expert 
panel pilot validation on 60 cases and a clinical validation on 241 cases were performed.
Results: The developed questionnaire and code validated in silico resulted in a suitable tool to 
support the medical diagnosis. The clinical validation of the ES was performed in an academic 
setting that included six different reference centers for respiratory diseases. The results of the ES 
expressed as a score associated with the risk of suffering from COLD were matched and compared 
with the final clinical diagnoses. A set of 60 patients were evaluated by a pilot expert panel valida-
tion with the aim of calculating the sample size for the clinical validation study. The concordance 
analysis between these preliminary ES scores and diagnoses performed by the experts indicated 
that the accuracy was 94.7% when both experts and the system confirmed the COLD diagnosis 
and 86.3% when COLD was excluded. Based on these results, the sample size of the validation 
set was established in 240 patients. The clinical validation, performed on 241 patients, resulted 
in ES accuracy of 97.5%, with confirmed COLD diagnosis in 53.6% of the cases and excluded 
COLD diagnosis in 32% of the cases. In 11.2% of cases, a diagnosis of COLD was made by the 
experts, although the imaging results showed a potential concomitant disorder.
Conclusion: The ES presented here (COLD
ES
) is a safe and robust supporting tool for COLD 
diagnosis in primary care settings.
Keywords: chronic obstructive lung diseases, expert systems, diagnosis
Introduction
The umbrella term chronic obstructive lung disease (COLD) includes different 
pulmonary diseases whose distinctive feature is the persistent obstruction of lower 
airways. Irrespective of etiology or pathogenesis of the specific disease, the acronym 
COLD is sufficiently informative to draw attention to a worldwide health problem 
that must be addressed.1,2
COLD mainly involves chronic bronchitis and emphysema, although specific 
asthma patterns, as well as various less common lung diseases, can also be included. 
COPD and asthma are distinct nosology entities; however, they often present with 
a continuum of different patterns in which risk factors, trigger exposure, functional 
and biological abnormalities and symptoms interact in a complex, dynamic and het-
erogeneous manner.2 Owing to the variability and heterogeneity of clinical features 
and the limited access to lung functional tests, COLD remains often underdiagnosed, 
especially in primary care.2–4
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Approximately 10% of the general population presents 
with signs of COPD and 26% of individuals suffering from 
chronic respiratory symptoms aged $45 years have indica-
tions of COLD. However, only approximately a quarter to 
half of these patients have received a proper diagnosis of 
chronic obstructive disease.5 In this scenario, novel case-
finding strategies for the identification of hidden cases may 
benefit from new technology-based supporting tools estimat-
ing disease probability.
In recent years, artificial intelligence (AI) tools were 
used to support physicians in the diagnosis of COLD, by 
defining the functional respiratory defect and analyzing the 
results of a combination of spirometry,  bronchodilatation 
and bronchoprovocation tests, as well as Impulse Oscillom-
etry System (IOS).6 In a similar study, 323 cases of COPD 
were evaluated by using a clinical decision support system 
(CDSS), obtaining 90% specificity and 96% sensitivity.7 
More recently, a novel tool was tested on 60 patients with 
COPD by using more sophisticated calculation techniques 
and a questionnaire based on 27 patient characteristics 
(including sex, dry cough, wet cough, fever, wheezing, 
smoking, weight loss, short of breath, chest pain, dyspnea, 
personal history of asthma, tuberculosis [TB], COPD, latent 
TB, childhood asthma patient and family history of these 
diseases) resulting in .90% accuracy.8 Although interesting 
results were obtained in these studies, a simple and accu-
rate system to support physicians in their diagnostic work 
has not been fully developed yet. Expert systems (ESs), 
representing a branch of AI, are designed by combining 
the knowledge of human experts with inference engines 
suitable to answer questions on a specific topic.9 ESs are 
consulted to obtain advice, suggestions and recommenda-
tions on issues that fall within the experts’ knowledge10 and 
are widely used in many different fields of human activities 
(from the Internet to finance). The development of large 
specific data management tools is increasing the interest of 
the medical community.11
The aim of the present study was to develop an ES to 
support the identification of individuals suffering from COLD 
in primary care settings.
To this aim, four steps were performed: questionnaire 
development, code development and in silico validation, 
expert panel pilot validation and real-life clinical validation. 
ES cannot be intended as a diagnostic tool. This ES quantifies 
the chance that an obstructive respiratory disease (eg, COPD 
or asthma) occurs, by means of a probabilistic value. There-
fore, this ES allows addressing patients in a more appropri-
ate and objective way to in-depth investigations leading to 
diagnosis. The study was approved by the Ethics Committee 
of Catanzaro (Italy), No 220, of November 16, 2016.
Methods
Questionnaire development
Key questions for COLD diagnosis were based on pub-
lished disease recommendations.12–14 Age, sex, presence 
and characteristics of chronic cough, sputum and dyspnea, 
environmental exposure (smoke and/or known allergen 
sensitizations) and available diagnostic tests (chest X-ray, 
pre- and post-bronchodilator spirometry) were considered 
(Figure 1). A panel of Italian pulmonologists, with docu-
mented experience in COLD management and expertise in 
the field, developed, adopting a two-round Delphi method, 
the following rules:
1. Presence of chronic cough: even if more frequent in 
COPD patients (where is usually productive), cough may 
also be present in asthmatic patients (in whom dry cough 
attacks are often reported).15
2. Presence of dyspnea: while persistent and progressive 
dyspnea is considered more common in COPD, occa-
sional dyspnea is more prevalent in asthma. At rest, dys-
pnea is considered worse than exertional dyspnea.16,17
3. Environmental and voluntary noxious exposures: the 
sensitization to inhalant allergens is more frequently 
observed in asthmatic than in COPD patients. The expo-
sure to smoke is relevant to the diagnosis of COPD in 
the presence of chronic bronchial obstruction. Thus, the 
number of pack-years ($15) is more frequently associ-
ated with COPD, and the risk persists also in former 
smokers. Smoke exposure can also occur in asthmatic 
patients, although to a lesser degree.12,13,18
4. Age: if the subject is ,45 years of age, the risk of having 
COPD can be considered reasonably low.19
5. Asthma onset is more prevalent at younger ages, 
although the development of late onset of asthma in 
individuals .65 years of age is not uncommon.20,21
6. Lung functional test: a post-bronchodilator persistent bron-
chial obstruction is typical of COPD but can also be registered 
in uncontrolled/severe asthma and other forms of COLD. 
Normal spirometry rules out the diagnosis of COPD.22
7. Chest X-ray: the absence of pleural and lung thickening/
infiltrates increases in the presence of respiratory symp-
toms and typical functional patterns increased the odds of 
having COLD. Vice versa, any radiologic sign (eg, bron-
chiectasis, pleural effusions, cysts, interstitial thickening) 
makes necessary primarily to investigate the occurrence 
of diseases other than COLD.23
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
25
.2
11
.2
4 
on
 2
8-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1749
Chronic obstructive lung disease “expert system”
The expert panel assigned a specific weight to each item 
based on their experience in the field.
Code development
Starting from the weights and the rules described in the 
Methods section, the ES code was written using WebFlex, an 
advanced knowledge specification language (LPA, London, 
UK). The ES is based on frame rules (representing the knowl-
edge base) driving the system itself and on forms for input and 
output. A user interface (UI) optimization was provided by a 
software house (Prospero Multilab Srl, Bologna, Italy).
The risk of COLD was calculated by adding a predefined 
positive or negative score to symptoms, results of the lung 
function test and chest X-ray findings, when available. In 
the presence of each required result, the ES produced a score 
ranging from 0 to 200 (where 200 was the highest possibility 
of having a COLD in the presence of all required signs and 
symptoms). Cutoff score, risk of suffering from COLD and 
score interpretation are shown in Table 1. In addition, accord-
ing to the rules decided by the experts and the combination of 
specific symptom patterns, lung function and X-ray results, 
the ES also provided some specific warnings (Table 2).
In silico validation
The in silico validation was performed to evaluate the con-
sistency of the actual results of the ES questionnaire with 
the expected answers. Different information technology (IT) 
strategies were used (not shown) to mimic all the different 
possible answers to the questionnaire. The output of this vali-
dation provided the proof that the ES was performing prop-
erly and that conditions of no results were not occurring.
expert panel pilot validation
A pilot validation test was carried out on 60 different patients 
(training set). The different weights were iteratively modified 
(if needed) through cycles of validation, aimed at bringing 
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Figure 1 Website design of the COlDeS, an obstructive lung disease diagnosis-supporting tool.
Notes: two pages of the questionnaire are shown. the second page of the questionnaire (right) includes possible further questions that are determined by the answers 
given on the first page of the questionnaire (left).
Abbreviations: COlD, chronic obstructive lung disease; eS, expert system.
Table 1 Cutoff score, risk of COlD, and interpretation 
implemented in the eS version used in the study (COlDeS)
Score range Probability 
of COLD (%)
Interpretation
ES prediction without lung function test and X-rays
0–75 ,30 Unlikely
75–110 ,50 Unlikely
110–130 .70 likely
ES prediction without lung function test and with X-rays
0–50 ,20 Unlikely
50–100 ,40 Unlikely
100–150 .70 likely
ES prediction with all data (with or without bronchodilation)
0–60 ,10 Virtually excluded
60–115 ,40 Unlikely
115–160 .70 likely
160–200 .85 Very likely
Abbreviations: COlD, chronic obstructive lung disease; eS, expert system.
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the ES results as close as possible to experts’ results. At the 
end of this validation step, suitable for the identification of 
the best scores for each sign or symptom that was relevant 
for the diagnosis, the definition of the final weights used 
in the ES tested in clinical validation was achieved. As a 
further result, the pilot validation phase allowed estimating 
the degree of concordance between the results of the ES and 
the results of the experts. On the basis of this concordance, it 
was calculated that the sample size for the clinical validation 
study was 260 patients for an incidence of 85%, type 1 (alpha) 
error of 0.01 and type 2 (power) error of 95%.
Clinical validation of the eS
For this aim, two forms of the system were built and made 
available in a closed network: the first was defined as the 
screening form where physicians uploaded the clinical and 
functional data registered during the visit of the patient. On 
this dataset, the ES ran the algorithm and calculated the prob-
ability of COLD. A second form defined as reviewer’s form 
was used to upload the results of the reviewer’s (the expert) 
final diagnosis, based not only on data uploaded during the 
first visit but also on all other information collected during 
the diagnostic process. Both forms saved data in two distinct 
databases in a Microsoft SQL Server. Both researchers 
involved in the screening procedures, and reviewers had a 
password to enter the system and upload the recorded infor-
mation. The evaluation was blindly performed by two groups 
of scientists to evaluate whether the ES, loaded with real-life 
values, produced results in line with the experts’ opinion and 
experience. Starting from the results obtained in the pilot 
phase, the ethics committees accepted the protocol and the 
patient’s informed consent, and six Italian academic refer-
ence centers were engaged in the validation of the COLD
ES
. 
The centers were requested to enroll 43 consecutive patients 
attending their outpatient clinics for suspected obstructive 
lung diseases. After fulfilling the informed consent, patients 
were asked to answer the questions posed by the system. The 
physician participating in the study completed the screening 
form by identifying each patient by a code so that patients’ 
IDs were made known only in the relevant clinic. In a sec-
ond phase, when the whole clinical diagnostic procedure 
was performed, an independent reviewer entered a specific 
form for each patient (identified by the same code used in 
the screening phase) and reported with the final diagnosis. 
Finally, the COLD
ES
 outcome and the clinical experts’ 
opinion were compared and the degree of concordance was 
evaluated. Figure 2 describes the different methodological 
steps included in the analysis.
Table 2 the diagnostic warnings provided by COlDeS
Warnings Description
Warning 1 the presence of an accessional dyspnea could be 
associated with asthma
Warning 2 the presence of a sensitization to inhalant allergens is 
frequently associated with asthma
Warning 3 A younger age (,45 years) is less frequently associated 
with COPD, but the presence of a concomitant 
obstructive pattern always needs further investigation 
(alpha-1 antitrypsin assessment)
Warning 4 Older age (.60 years) is more frequently associated 
with COPD, but physiologically reduced functional lung 
volumes and flows could mimic COPD
Warning 5 the complete reversibility of bronchial obstruction is 
essential in the differential diagnosis between COPD and 
asthma. Absent or partial reversibility can be present in 
both asthma and COPD
Warning 6 lung function tests are essential for the diagnosis of COlD
Warning 7 Chest X-rays are essential in excluding/confirming lung 
diseases other than COlD
Abbreviations: COlD, chronic obstructive lung disease; eS, expert system.
??????????????????????????????????????????????????????????????
??????????????????????????????????????????
?????????????????????????????? ????????????????????
????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????
Figure 2 Algorithm describing the different steps in the process of validation of the tool.
Abbreviations: COlD, chronic obstructive lung disease; eS, expert system.
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Results
The different weights and diagnostic warnings were obtained 
at the end of the expert panel pilot validation by iterative cycles 
of improvement. The concordance analysis between the ES 
scores and the diagnoses performed by the experts in the pilot 
validation step showed an accuracy ranging between 86% and 
95% for COLD and not-COLD, respectively. As specified in 
the “Methods” section, these findings allowed calculation of 
the power of the study in a total of 260 individuals.
In the clinical phase, 258 records were registered. Of 
these, data from 241 patients were eligible for analysis. 
In ten cases, symptoms alone were uploaded to the ES; in 
59 patients, symptoms and absence of obstruction at baseline 
spirometry were recorded; in 76 patients, symptoms and 
obstruction at baseline spirometry were recorded without 
any concomitant evaluation of bronchial reversibility; in 
96 patients, symptoms and bronchial obstruction at baseline 
spirometry with persistence of obstruction after salbutamol 
400 μg were recorded in 72 patients, while in 24 subjects, 
the airway obstruction was fully reversible.
Among the 241 patients, chest X-ray was performed in 
142 individuals. X-ray results were available in nine out of 
ten patients with clinical findings only. In the group of sub-
jects with normal spirometry values, 33 had X-ray results, 
while 26 did not. Among the 73 patients with bronchial 
obstruction, 36 had X-ray results, and among those with 
fully reversible bronchial obstruction, nine patients had 
X-rays. In the 75 patients with baseline bronchial obstruc-
tion where the bronchodilator test was not performed, 55 
had X-ray results.
In 28 (11.6%) subjects, X-ray allowed the ES to suspect 
a disease other than COLD (lung fibrosis, bronchiectasis, 
lymphangioleiomyomatosis [LAM], cystic fibrosis, sarcoi-
dosis, Kartagener syndrome).
In a total of 208 out of 241 (86.3%) cases, the ES correctly 
identified patients with COLD and excluded individuals 
without COLD. In 131 (54.35%) cases, the ES identified 
a condition fitting with COLD in a very probabilistic man-
ner. In this group, the expert evaluation brought to COPD 
diagnosis in 111 cases and severe asthma in 20 cases. In 
77 (31.95% of the total) cases, both the ES and the experts 
excluded a COLD. In 27 (11.20%) subjects, the experts 
posed a final diagnosis of COLD, even if the X-ray analysis 
showed a pattern different from COLD (ie, post TB fibro-
sis). Five subjects (2.07%) had incorrect data (ie, absence 
of spirometry obstruction at screening and fixed obstruction 
shown by the expert). Therefore, the overall accuracy of the 
ES was 97.50%.
Chi-square analysis showed a significant association 
between the relative risk defined by the ES according to the 
weights defined during the phase of ES development and 
the specialist judgment (Table 3). The sample was not suffi-
ciently large to evaluate the relative weight of each parameter 
of the tool (ie, spirometry, bronchodilation test) in ameliorat-
ing the accuracy of the diagnosis-supporting tool.
Discussion
Epidemiologic data constantly point out that the health 
resources and the physicians’ attempts to detect COLDs 
unable to predict the hidden prevalence of such conditions, 
as patients may not see the doctor until the disease is in an 
advanced stage. A COLD is usually diagnosed late because 
patients may adapt to their limiting condition or physicians 
may not properly detect the respiratory symptoms until lung 
function becomes severely impaired, sometimes below a 
half of normal values. As a consequence, up to 70% of the 
COLD population remains undiagnosed.5 Considering the 
limited resources for preventive medicine available in many 
countries, widespread programs of COLD detection are forced 
to adopt the strategy of an optimal cost-effectiveness ratio.
The ES for the diagnosis of COLD described in this 
work (COLD
ES
) was aimed at supporting the diagnosis 
also in primary care. The results of the validation analysis 
provided an ES accuracy of 86.3%. However, by removing 
confounding events and diagnoses that cannot be made based 
on only the questionnaire used in this study, the overall 
accuracy of the ES was 97.6%. While it cannot be excluded 
that a better accuracy might be obtained by adding further 
Table 3 Consolidated results in 231 unselected samples
Score Relative 
risk (%)
Number 
of patients
COLD No COLD % actual % expected Concordance χ2
0–60 ,10 51 5 46 9.8 10 Ok
61–115 ,40 67 24 43 35.8 40 Ok
116–160 .70 66 49 17 74.2 70 Ok 0.48
160–200 .85 47 40 7 85.1 85 Ok 0.92
total 231 118 113
Abbreviation: COlD, chronic obstructive lung disease.
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variables, eg, those reflecting the second-level lung function 
assessment, the parsimonious model proposed here proved 
to be very robust.
It is well known that COLD diagnosis (in particular, the 
distinction between COPD and severe asthma) cannot be 
made starting from clinical signs and symptoms, spirometry 
and X-ray data, as it requires more sophisticated diagnostic 
tools. The percentage accuracy of the system described here 
seems promising for a future use of COLD
ES
 in different 
settings, including primary care. Obviously, this ES is not 
intended as a substitute for the clinician’s role; on the con-
trary, it may actually serve as an additional tool when COLD 
is suspected or in raising the suspicion.
Others have developed tools based on AI in the field of 
respiratory diseases. For example, a powerful ES was devel-
oped for the evaluation of spirometry data in the context of 
the clinic.7 In this study, the knowledge was built based on 
a single expert, while in the present work, a panel of experts 
was involved in the pilot validation study for the definition of 
different weights. In addition, data used to feed the inferential 
engine were second-level functional tests, while the aim of the 
present study was to suggest suspicion of COLD during the 
first screening visit of the patient. A further sophisticated study 
described the use of powerful artificial neural networks for the 
implementation of an ES suitable to suggest the diagnosis of 
COPD, TB, asthma and pneumonia.8 However, in this work, 
the validation was based on 60 cases, a number that seems too 
small for validating four different diseases. COLD
ES
 instead 
was supported by an extensive clinical validation made on a 
collection of 241 cases, resulting in a robust and accurate tool. 
In addition, the ES approach has several strengths: 1) the results 
are more consistent and traceable compared to an individual’s 
assessment; 2) it allows gaining productivity and performance; 
3) it is less expensive and quicker than referring to an expert, 
and 4) it can be made available anytime and anywhere.
One of the limitations lies in the fact that the rules were 
proposed by a panel of experts and need validation in larger 
samples. However, the system has the capability of being 
constantly updated, remaining efficient under the constant 
revision process.
To our knowledge, this is the first example of the devel-
opment of an ES allowing establishment of probability of 
suffering from a COLD in a single individual. The current 
findings carry important clinical implications. The high 
accuracy of this tool allows moving to the implementation 
of the diagnosis- supporting ES in primary care settings. As 
already mentioned, the ES does not allow making of a definite 
diagnosis of COLD or to discriminate among different chronic 
obstructive diseases. In the hands of general practitioners 
(GPs), the ES can quickly contribute to identify subjects who 
are candidates for suffering from COLD. In other words, 
the high suspicion of COLD can be obtained in the office 
during general consultation, not requiring in this stage any 
supplemental test. This is of great importance in the real-life 
scenario, in which availability of time and specific skills may 
be poor. In addition, local and regional health systems suffer 
from the lack of standardized and organized collaborative 
pathways between GPs and pulmonologists, delaying lung 
function evaluation and consultation by the specialist.
COLD
ES
 has been conceived by specialists as a support 
also for primary care physicians, thus fostering the collabora-
tion between these two entities. Most importantly, this tool 
is designed to unveil the unexplored milieu of COLD in the 
general population, by supporting the GPs in raising the 
suspicion quickly and reliably.
Conclusion
Further investigations on larger samples are required to 
confirm and expand the current results, thus testing the per-
formance of the ES in real-life primary care contexts.
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